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variables base case were robust in an interval of o 20%. CONCLUSIONS: Viscosup-
plementation is a cost-saving alternative for for the treatment of moderate osteoar-
thritis of knee compared to arthroscopy/lavage in the perspective of Brazilian’s Private 
Sector.
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OBJECTIVES: Assess RA health care resource utilization in a sample of Brazilian 
private health system beneﬁciaries. METHODS: Three Health Management Organiza-
tion (HMOs) databases were analyzed retrospectively, involving 1,057,033 people, 
corresponding to approximately 3% of total private health system beneﬁciaries in 
Brazil. The analysis was done in 35 months (from January 2004 to November 2007). 
The following health care resources were considered: clinical appointment, hospital-
ization, emergency service, drugs and laboratory exams. All RA patients were com-
pared to non-RA patients in terms of health care resource usage. RESULTS: From 
1,057,033 people analyzed, 4,817 (0.46%) were classiﬁed as having RA, being the 
prevalence rate among women and men 3.5: 1. Those patients concentrated 4.8% 
of the total costs of whole population analyzed. The cost per month/per member 
(cost pm/pm) of RA patients was 6.6 times higher than non-RA population. In addi-
tion, RA patients, compared to non-RA patients, demonstrated 3.4 and 13 times 
higher clinical appointments and hospitalization, respectively. Considering other 
chronic diseases (hypertension, heart failure, asthma, bronchitis and diabetes mellitus 
patients), RA patients demonstrated 1.4 and 3.1 times higher clinical appointments 
and hospitalization, respectively. Comorbiditidy was associated to 33% of RA 
patients, mainly cardiovascular disorders (CVD). CONCLUSIONS: Our results rein-
force the international literature data demonstrating that despite 0.46% prevalence, 
RA has high individual cost (concentrating 4.8% of total costs of whole population 
analyzed) due to multifactor variables, including pharmaceutical assistance and 
comorbidities. Regarding health care resources the study showed that RA patients 
had a higher utilization than non- RA patients, conﬁrming the literature about the 
important cost of the disease in the clinical practice. In addition we suggest an impor-
tant association between RA and comorbidities, especially CVD. In conclusion, RA 
may require speciﬁc strategies by decision makers to optimize its management and 
reduce cost.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess whether patients with rheumatoid arthritis (RA) who are 
newly initiated on tumor necrosis factor (TNF) antagonists adalimumab, etanercept, 
and inﬂiximab perceive differences in treatment outcomes. METHODS: Study data 
were derived from the 2006 RA Survey (Waves 7 and 8), a nationally (United States) 
representative survey of adults with RA conducted by Consumer Health Sciences 
International. Only patients currently taking TNF antagonists were included. Patients 
with prior self-reported TNF-antagonist use were excluded to avoid potential response 
bias. Responses to 19 questions on various aspects of treatment related to effective-
ness, safety, and patient convenience were collected and converted from an ordered-
response scale to a binary scale (1  favorable response [“strongly agree” or “agree”] 
vs. 0  nonfavorable response [“neither agree nor disagree,” “disagree,” or “strongly 
disagree”]). Chi-square tests identiﬁed signiﬁcant differences between treatments in 
the percentages of patients reporting favorable responses (p  0.05), and odds ratios 
(ORs) were determined using logistic regression, with controls for age and duration 
of RA. RESULTS: The study sample included 303 patients currently taking adalim-
umab (n  83), etanercept (n  133), or inﬂiximab (n  87). The odds of reporting 
favorable outcomes were approximately 2 times greater with adalimumab vs. etaner-
cept for convenience (OR  1.96), no long-term risks (OR  1.93), no short-term 
adverse effects (OR  1.84), symptom relief within 2 weeks (OR  1.98), and increased 
energy within 2 weeks (OR  2.29). The odds of reporting favorable outcomes with 
adalimumab vs. inﬂiximab were greater for convenience (OR  2.78,) and no long-
term risks (OR  2.27). The odds of reporting favorable outcomes with inﬂiximab vs. 
etanercept differed only for symptom relief within 2 weeks (OR  2.27) and increased 
energy within 2 weeks (OR  2.21, p  0.05 for all comparisons). CONCLUSIONS: 
RA patients initiating TNF-antagonist therapy perceived adalimumab to be more 
convenient than etanercept or inﬂiximab. Adalimumab was also perceived to offer 
rapid symptom relief and fewer risks compared with etanercept, and fewer long-term 
risks vs. inﬂiximab.
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OBJECTIVES: To examine the treatment effect of ustekinumab on physical disability 
and QoL in PsA patients using data from a phase II trial. METHODS: Patients with 
active PsA were randomized to ustekinumab 90mg/63mg (n  76) at wks0, 1, 2, and 
3, followed by placebo at wks12 and 16, or placebo at wks0, 1, 2, and 3, followed 
by ustekinumab 63mg at wks12 and 16 (n  70). Physical disability was assessed using 
the disability index from the HAQ (0:no difﬁculty to 3: unable to do) and DLQI 
(range: 0–30) assessed QoL. Clinically meaningful improvement was deﬁned as a 
0.25-point improvement in the disability index, and a 5-point improvement in the 
DLQI. Continuous variables were compared using ANOVA on the van der Waerden 
normal scores. Binary endpoints were compared using Chi-square test. RESULTS: 
Baseline PsA patients had moderate physical disability (mean disability index 1.0) and 
impaired QoL (mean DLQI 11.5). Ustekinumab-treated patients demonstrated signiﬁ-
cant improvement in physical disability as early as 1wk after the ﬁrst dose. After 4 
treatments at wks0, 1, 2 and 3, 60% of patients in the ustekinumab group vs. 28% 
in the placebo group achieved clinically meaningful improvement in disability (HAQ 
responders) at wk12 (p  0.001), and the mean reduction in disability index at wk12 
was 0.31 in the ustekinumab group vs. 0.04 in the placebo group (p  0.001). At 
wk12, 67.0% of HAQ responders maintained response through wk36. 60.3% of 
patients in the ustekinumab group vs. 23.6% in the placebo group achieved a clinically 
meaningful improvement in QoL (DLQI responders) at wk12 (p  0.001). At wk12, 
45.2% of DLQI responders in the ustekinumab group maintained response through 
wk36. Patients in the placebo group who crossed over to ustekinumab at wk12 and 
16 improved in disability and QoL at wk36 similar in magnitude to those initially 
randomized to ustekinumab. CONCLUSIONS: Ustekinumab signiﬁcantly improved 
physical disability and QoL in patients with PsA.
NEUROLOGICAL DISORDERS – Cost Studies
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OBJECTIVES: To determine the budget impact of incorporating levodopa/carbidopa/
entacapone FDC in Distrito Federal’s public reimbursement system for Parkinson 
disease treatment. METHODS: In present analysis, it was considered the quantity 
reimbursed for Distrito Federal in 2007 in Parkinson Disease treatment, based on 
DATASUS (National public health care database). Results were converted in US Dollars 
(R$2.27/USD 1.00). It was considered the medications costs used in Distrito Federal’s 
bidding: USD 0.04/tablet for both combinations of levodopa/carbidopa; USD 0.53/
tablet for both combinations of levodopa/benserazide; USD 0.95/tablet for entacapone. 
Levodopa/benserazide’s presentations have different prices, however to simplify the 
analysis, we took the price of the most used presentation (78% in units) and considered 
it for both. According to DATASUS, considering all levodopas’ combinations reim-
bursed in Distrito Federal in 2007, 62% was levodopa/carbidopa and 38% was 
levodopa/benserazide. The price of all levodopa/carbidopa/entacapone FDC’s were 
ﬁxed in USD 0.97/tablet. A one-way sensitivity analysis was performed. RESULTS: 
In Distrito Federal, the quantities reimbursed in 2007 for entacapone were 43,380 
and for all levodopas’ combinations were 395,510. Considering the prices used in 
Distrito Federal’s bidding, the total of expenses was US$131,311. In this scenario, if 
levodopa/carbidopa/entacapone FDC is used in the place of free dosage combinations, 
then the total of expenses was estimated in US$122,369. The sensitivity analysis on 
cost variables in an interval of o 20% was robust with the base analysis. CONCLU-
SIONS: This budget impact analysis showed a potential economy of US$8942 if 
levodopa/carbidopa/entacapone FDC is incorporated in Distrito Federal’s public reim-
bursement system. Besides, the use of FDC can provide higher adherence of patients 
to the treatment, once it is easier administrating one tablet instead of two or more; 
the patients prefer to take less quantity of tablets; the switches of dosage are easier.
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OBJECTIVES: To determine the budget impact of incorporating levodopa/carbidopa/
entacapone FDC in São Paulo’s public reimbursement system for Parkinson disease 
treatment. METHODS: In present analysis, it was considered the quantity reimbursed 
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for São Paulo’s state in 2007 in Parkinson Disease treatment, based on DATASUS 
(National public health care database). Results were converted in US Dollars (R$2.27/
USD1.00). It was considered the medications costs used in São Paulo state’s bidding: 
USD0.04/tablet for both combinations of levodopa/carbidopa; USD 0.51/tablet 
for both combinations of levodopa/benserazide; USD0.96/tablet for entacapone. 
Levodopa/benserazide’s presentations have different prices, however to simplify the 
analysis, we took the price of the most used presentation (89% in units) and consid-
ered it for both. According to DATASUS, considering all levodopas’ combinations 
reimbursed in São Paulo’s state in 2007, 40% was levodopa/carbidopa and 60% was 
levodopa/benserazide. The price of all levodopa/carbidopa/entacapone FDC’s were 
ﬁxed in USD 0.97/tablet. A one-way sensitivity analysis was performed. RESULTS: 
In São Paulo’s state, the quantities reimbursed in 2007 for entacapone were 1,431,692 
and for all levodopas’ combinations were 8,765,930. Considering the prices used in 
São Paulo’s bidding, the total of expenses was US$4,217,586. In this scenario, if 
levodopa/carbidopa/entacapone FDC is used in the place of free dosage combinations, 
then the total of expenses was estimated in US$3,771,147. The sensitivity analysis 
on cost variables in an interval of o 20% was robust with the base analysis. 
CONCLUSIONS: This budget impact analysis showed a potential economy of 
US$446,438 if levodopa/carbidopa/entacapone FDC is incorporated in São Paulo’s 
public reimbursement system. Besides, the use of FDC can provide higher adherence 
of patients to the treatment, once it is easier administrating one tablet instead of two 
or more; the patients prefer to take less quantity of tablets; the switches of dosage are 
easier.
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OBJECTIVES: Compare the cost-effectiveness of two distinct therapies, Intravenous 
Immunoglobulin (IVIg) and Plasma Exchange (PE) in the treatment of Guillain-Barré 
Syndrome, concerning the public health care system. METHODS: A cross-sectional, 
economical analysis was conducted, including patients treated for GBS in the period 
from June, 2003 through June, 2008 in a public university afﬁliated hospital in south 
Brazil. The cost-effectiveness of the use of IVIg and PE in such patients was studied 
through the cost minimization method, considering direct medical costs only (albumin, 
IvIG, supplies, professional, hotel and capital costs; 2008 prices). Data were collected 
by chart reviews. RESULTS: The total treatment cost for PE in a single patient was 
US$6,058.85 (o1,701.78 SD), and the same expense for IVIg was US$18,344.57 
(o12,259.56 SD) (p  0.035). Total inpatient cost was US$25,729.79 (o18,714.54 SD) 
in the PE group, and US$34,768.16 (o27,766.01 SD) (p  0.530) in the IVIg group. 
The main clinical outcome was improvement in the 7-point disability grade scale. The 
median of that measure in patients admitted with a severity grade 3 treated either with 
PE and IVIg was the same. Secondary outcomes, such as in-hospital stay, ICU stay, 
and number of days on mechanical ventilation revealed no statistically signiﬁcant dif-
ference between treatments. CONCLUSIONS: As the mean expenses of both thera-
peutic options are compared, one clearly stands-out as less onerous. We concluded 
that, in a public university afﬁliated hospital, plasma exchange is more cost-effective 
than intravenous immunoglobulin.
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: The association between income level (IL) and tobacco consumption, 
and its consequences, varies over time and between regions of the world. The aim of 
this study was to assess this association. METHODS: We included observational 
studies, published in the last 20 years, with direct assessment of IL. We searched 
in the main literature databases, conferences index, tobacco control agencies, and 
contacted experts. Two independent researchers screened titles and abstracts (agree-
ment  0.9). The full text of selected studies and its risk of bias (using a STROBE-based 
checklist) were assessed by two researches. One reviewer extracted data, and a second 
one checked it. Disagreements were solved by consensus. We performed a random 
effects meta-analysis based on adjusted ORs using Stata 9.0. We performed pre-
planned subgroup and sensitivity analysis to evaluate heterogeneity (I2  50%) by 
calendar decade, continent, WHO region, country standardized mortality rate, risk of 
bias, gender, and age. RESULTS: Out of 9575 references we ﬁnally included 137 
articles (86% cross-sectional studies). A total of 125 papers (N  31,146,096 subjects) 
reported smoking prevalence, being higher among people with Low-IL than High-IL 
(OR 1.48, 95%CI 1.38–1.59). This ﬁnding was marked especially after the ‘90s 
decade -except for the Eastern Mediterranean Region. Considering only studies 
with the three IL categories, a gradient was observed (for both genders): Low-IL vs. 
High-IL OR 1.54 (1.39–1.72), and Middle-IL vs. High-IL 1.25 (1.16–1.33). Twenty 
studies (N  987,885) reported adjusted data for tobacco attributable diseases 
(coronary heart disease; pulmonary disease; low birth weight, cardiovascular and 
all cause death). All studies, except three with null effect, exhibited statistically sig-
niﬁcant higher ORs of tobacco outcomes as household income decreased. The median 
proportion of tobacco/total household expenditures was 10.7%, 3.7%, and 1.8% in 
Low-IL, Medium-IL and High-IL respectively. CONCLUSIONS: This meta-analysis 
conﬁrmed and quantiﬁed an inverse relationship between IL and smoking prevalence 
and consequences.
RESPIRATORY-RELATED DISORDERS – Cost Studies
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OBJECTIVES: To estimate of budget impact of introduction Fluticasone/salmeterol 
combination to treatment of Chronic Obstructive Pulmonary Disease (COPD) into 
the Brazilian National Drug Formulary. METHODS: We used the PLATINO Survey 
to estimate the number patients with moderate, severe and very severe stages of COPD 
and GOLD recommendations to estimate the medication costs of change in São Paulo 
Protocol to Treatment of COPD. We used the cost-effectiveness results of the four 
therapeutic options: usual care (UC), long-acting anticholinergic drug, Tiotropium 
(TIO); long-acting beta-agonist, Salmeterol (SAL); and Fluticasone/Salmeterol 
(SERETIDE®). The measure effectiveness was the exacerbations. The perspective 
adopted was of the Brazilian Public Health Care System (SUS). The budget impact 
was calculated to four scenarios. A one-way sensitivity analysis was performed. 
RESULTS: The additional costs incorporation of ﬂuticasone/salmeterol (SERETIDE®) 
in SUS were between US$70,438 and US$5 millions. The best scenario (2) was 20% 
patients in usual care and 80% in Fluticasone/salmeterol (SERETIDE®). In sensitivity 
analysis some parameters (price, effectiveness) were changed and the scenario 2 
remains the best. In this scenario occurred in the incremental cost per patient was 
US$2.21 and incremental cost per reduction exacerbation was US$43.13. If we 
 analysed only medication costs the incorporation is cost saving (US$9 millions. 
 CONCLUSIONS: SERETIDE® offers the protection against exacerbations at low cost 
compared with TIO. If all costs are computed is needed an incremental budget of 
US$2.21 per patient. Their incorporation is cost saving and can to extend the phar-
macotherapy for to more patients. The results showed the need of guidelines to assure 
the best resource allocation.
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OBJECTIVES: To perform a comprehensive evaluation of tobacco-related disease 
burden in Argentina, including both its health effects and its economic impact 
METHODS: A ﬁrst order Monte Carlo, or probabilistic microsimulation of individual 
patients was built, incorporating the natural history, costs and quality of life impact 
of all the tobacco-related adult diseases: coronary and non-coronary heart diseases, 
cerebrovascular disease, COPD, pneumonia/inﬂuenza, lung cancer as well as 9 other 
neoplasms. Systematic searches were performed in bibliographic database, grey litera-
ture and experts. RESULTS: The model showed adequate internal validity, with all 
simulated events rates falling within o10% of the source publications. R2 between 
predicted and observed values ranged from 0.758 to 0.999. Third order validation 
showed an excellent correlation between published data and model results. Health 
conditions related to smoking were responsible of 129,630 annual deaths in Argentina, 
25% of them (32,167) attributable to tobacco. The annual costs for the country were 
of about $9.5 billion pesos (Argentinean pesos, 2006), smoking being responsible for 
34%. Male smokers lost 5.5 years of life expectancy as compared to their non-smoking 
counterparts. A total of 721,285 total annual DALYs were attributable to tobacco 
use, among which the main conditions were cardiovascular disease, lung cancer and 
COPD. Premature deaths accounted for three quarters of DALYs. CONCLUSIONS: 
These results conﬁrm the local relevance of smoking as an important health an eco-
nomic burden in our country. They may be of great importance as strategic inputs for 
decision-makers, facing the ratiﬁcation of the Framework Convention on Tobacco 
Control goals.
